CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
-
Matthieu Blazy reaches for the stars in Chanel debut
-
Macron gives outgoing French PM final chance to salvage government
-
Illinois sues to block National Guard deployment in Chicago
-
Exiled Willis succeeds Dupont as Top 14 player of the season
-
Hamas and Israel open talks in Egypt under Trump's Gaza peace plan
-
Mbappe undergoing treatment for 'small niggle' at France camp: Deschamps
-
Common inhalers carry heavy climate cost, study finds
-
Madagascar president taps general for PM in bid to defuse protests
-
Greta Thunberg lands in Greece among expelled Gaza flotilla activists
-
UEFA 'reluctantly' approves European league games in US, Australia
-
Hundreds protest in Madagascar as president to announce new premier
-
Greta Thunberg lands in Greece among Gaza flotilla activists deported from Israel
-
UNESCO board backs Egyptian ex-minister for top job: official
-
Facing confidence vote, EU chief calls for unity
-
Cash-strapped UNHCR shed 5,000 jobs this year
-
Mbappe to have 'small niggle' examined at France camp: Deschamps
-
Brazil's Lula asks Trump to remove tariffs in 'friendly' phone call
-
Paris stocks slide as French PM resigns, Tokyo soars
-
'Terrible' Zverev dumped out of Shanghai by France's Rinderknech
-
What are regulatory T-cells? Nobel-winning science explained
-
Indirect talks on ending Gaza war begin in Sharm El-Sheikh: Egypt media
-
OpenAI signs multi-billion dollar chip deal with AMD
-
Salah under fire as Liverpool star loses his spark
-
Paris stocks drop as French PM resigns, Tokyo soars
-
ICC finds Sudan militia chief guilty of crimes against humanity
-
Zverev dumped out of Shanghai Masters by France's Rinderknech
-
One hiker dead, hundreds rescued after heavy snowfall in China
-
Hundreds stage fresh anti-government protests in Madagascar
-
Feminist icon Gisele Pelicot back in court as man appeals rape conviction
-
US government shutdown enters second week
-
Kasatkina ends WTA season early after hitting 'breaking point'
-
Paris stocks drop as French PM resigns
-
Death toll from Indonesia school collapse rises to 63
-
Medicine Nobel to trio who identified immune system's 'security guards'
-
UN rights council launches probe into violations in Afghanistan
-
UK author Jilly Cooper dies aged 88
-
Jilly Cooper: Britain's queen of the 'bonkbuster' novel
-
Streaming stars' Le Mans race scores Twitch viewer record
-
England rugby star Moody 'shocked' by motor neurone disease diagnosis
-
Leopard captured after wandering into Indonesian hotel
-
Israel, Hamas due in Egypt for ceasefire talks
-
Rescuers scramble to deliver aid after deadly Nepal, India floods
-
Tokyo stocks soar on Takaichi win, Paris sinks as French PM resigns
-
OpenAI offers more copyright control for Sora 2 videos
-
Australia prosecutors appeal 'inadequate' sentence for mushroom murderer: media
-
Rugby World Cup-winning England star Moody has motor neurone disease
-
Trump says White House to host UFC fight on his 80th birthday
-
Vast reserves, but little to drink: Tajikistan's water struggles
-
US government shutdown may last weeks, analysts warn
-
Arsenal host Lyon to start new Women's Champions League format
NYSE - LSE
| CMSD | -0.04% | 24.44 | $ | |
| CMSC | -0.17% | 23.83 | $ | |
| RELX | -0.04% | 46.39 | $ | |
| SCS | -0.71% | 16.99 | $ | |
| RBGPF | -2.92% | 76 | $ | |
| NGG | 0.65% | 73.91 | $ | |
| RIO | 1.25% | 66.95 | $ | |
| VOD | -0.62% | 11.29 | $ | |
| JRI | -0.78% | 14.189 | $ | |
| BCC | -3.2% | 75.22 | $ | |
| BCE | -0.75% | 23.185 | $ | |
| GSK | 0.23% | 43.448 | $ | |
| AZN | 0.21% | 85.49 | $ | |
| BTI | -0.14% | 51.17 | $ | |
| BP | 1.98% | 34.85 | $ | |
| RYCEF | -0.38% | 15.7 | $ |
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025
SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, today announced that David Cory, CEO, will participate in a fireside chat at the Cantor Global Healthcare Conference on Wednesday, September 3 at 11:30 AM ET in New York City. CASI will also host one-on-one meetings with investors at the conference.
A live webcast of the fireside chat will be available on the CASI Pharmaceuticals website at www.casipharmaceuticals.com under the "Investors" tab. A replay of the webcast will be available for 90 days after the live event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a publicly-traded, biopharmaceutical company focused on developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI is actively recruiting and dosing patients in a Phase 1 / 2 study in immune thrombocytopenic purpura (ITP). In parallel, CASI recently received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) and plans to initiate the study in third quarter of 2025.
More information on CASI is available at www.casipharmaceuticals.com.
COMPANY CONTACT:
Ingrid Choong, PhD
650-619-6115
[email protected]
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
H.E.Young--AMWN